This document presents an overview of the Pharmaceutical Quality Systems (ICH Q10) guideline. ICH Q10 establishes a quality management system model for the pharmaceutical industry and was intended to help companies comply with Good Manufacturing Practices. The objectives of ICH Q10 are to achieve product realization, establish control, and facilitate continual improvement. ICH Q10 also discusses management responsibility, risk management, challenges of implementing the new system, and the relationship between ICH Q10 and other quality standards like GMP.
WHO Good Manufacturing Practice Requirements
Good Manufacturing Practice is the part of quality assurance that ensures that products are consistently manufactured and controlled to the quality standards appropriate to their intended use.
Change control is a formal system by which qualified representatives of appropriate disciplines review proposed or actual changes that might effect a validated status. The intent is to determine the need for the action that would ensure that the system is maintained in a validated state.
Quality Management system in accordance to Vol. 4 EU Guidelines for GMP for Medicinal Products for Human and Veterinary Use Chapter 1 Pharmaceutical QS
ICH Q10/ Q7.
ISO 9001/2015
Master batch record,batch production record ,Quality Audit Type and plan &Rec...KarishmaFuse
Standard Operating procedure(SOP), Preparation review ,Approval Issuance of master batch Record MBR and Batch Production Record (BPR) and Quality Audit Type, plan and Objectives.
Role of quality system and audits in pharmamaceuticalganpat420
Introduction
cGMP Regulations
Quality Assurance Function
Quality Systems Approach
Management Responsibilities
Resources
Manufacturing Operations
Evaluation Activities
Transitioning to Quality Systems Approach
Audit Checklist for Drug Industry
Indian GMP Certification & WHO GMP CertificationVishal Shelke
Indian GMP Certification & WHO GMP Certification by Mr. Vishal Shelke
https://youtube.com/vishalshelke99
https://instagram.com/vishal_stagram
Sub :- Drug Regulatory Affairs
M.Pharm Sem II
Savitribai Phule Pune University
WHO Good Manufacturing Practice Requirements
Good Manufacturing Practice is the part of quality assurance that ensures that products are consistently manufactured and controlled to the quality standards appropriate to their intended use.
Change control is a formal system by which qualified representatives of appropriate disciplines review proposed or actual changes that might effect a validated status. The intent is to determine the need for the action that would ensure that the system is maintained in a validated state.
Quality Management system in accordance to Vol. 4 EU Guidelines for GMP for Medicinal Products for Human and Veterinary Use Chapter 1 Pharmaceutical QS
ICH Q10/ Q7.
ISO 9001/2015
Master batch record,batch production record ,Quality Audit Type and plan &Rec...KarishmaFuse
Standard Operating procedure(SOP), Preparation review ,Approval Issuance of master batch Record MBR and Batch Production Record (BPR) and Quality Audit Type, plan and Objectives.
Role of quality system and audits in pharmamaceuticalganpat420
Introduction
cGMP Regulations
Quality Assurance Function
Quality Systems Approach
Management Responsibilities
Resources
Manufacturing Operations
Evaluation Activities
Transitioning to Quality Systems Approach
Audit Checklist for Drug Industry
Indian GMP Certification & WHO GMP CertificationVishal Shelke
Indian GMP Certification & WHO GMP Certification by Mr. Vishal Shelke
https://youtube.com/vishalshelke99
https://instagram.com/vishal_stagram
Sub :- Drug Regulatory Affairs
M.Pharm Sem II
Savitribai Phule Pune University
Pharmaceutical 6 Sigma and QbD May 2005 Ball State UniversityAjaz Hussain
Pharmaceutical product and process quality – what is the current “sigma”?
Challenges in moving towards “6-sigma” levels?
What are the steps necessary for the pharmaceutical continuous improvement journey in the 21st Century?
ICH Q10 GUIDELINES (PHARMACEUTICAL QUALITY SYSTEM)
- Contents
- ICH
- ICH GUIDELINES
- Objective
Q10 GUIDELINE
- Introduction
- Scope
- Objective of Q10 Guideline
- Elements
- CAPA System
- Change Management System
- Continual improvement of pharmaceutical quality system
- References
THANK YOU :)
This full day presentation gives an overview of the process validation lifecycle approach, the FDA PV Guidance, the lifecycle approach to cleaning validation, equipment qualification, and validation quality systems.
Quality Management System including the Quality management and certificationAshwiniRaikar1
Concept of Quality, Total Quality Management, Quality by Design, Six Sigma concept, Out of Specification, Change control, Introduction to ISO 9000 Series of quality system standards, ISO 14000,NABL, GLP
Macroeconomics- Movie Location
This will be used as part of your Personal Professional Portfolio once graded.
Objective:
Prepare a presentation or a paper using research, basic comparative analysis, data organization and application of economic information. You will make an informed assessment of an economic climate outside of the United States to accomplish an entertainment industry objective.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
Acetabularia Information For Class 9 .docxvaibhavrinwa19
Acetabularia acetabulum is a single-celled green alga that in its vegetative state is morphologically differentiated into a basal rhizoid and an axially elongated stalk, which bears whorls of branching hairs. The single diploid nucleus resides in the rhizoid.
Embracing GenAI - A Strategic ImperativePeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
Group Presentation 2 Economics.Ariana Buscigliopptx
ICH Q 10 guidline
1. PRESENTED BY:-
BHANDARI UMESH M.
1ST YR M- PHARM.
DEPARTMENT OF PHARMACEUTICS.
RCPIPER, SHIRPUR
PHARMACEUTICAL QUALITY SYSTEMS
(ICH Q10)
2. CONTENTS
• INTRODUCTION
• OBJECTIVE
• DESIGN AND CONTENT CONSIDERATIONS
• RELATIONSHIP OF ICH Q10 TO GMP REQUIREMENTS
• RELATIONSHIP OF ICH Q10 TO REGULATORY APPROACHES
• MANAGEMENT RESPONSIBILITY
• MANAAGEMENT REVIEW
• CHALLENGES
• CONCLUSIONS
• REFERENCES
2
3. INTRODUCTION
• ICH - International Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use.
• The objective of ICH is to increase international harmonization of technical
requirements to ensure that safe , effective and high quality medicines are developed
and registered in the most efficient and cost-effective manner.
• Members of ICH
Japan
Europe
USA
• Meeting are conducted twice in year
• Last meeting conducted on 23rd oct 2015 3
4. Purpose
To increase international harmonization of technical
requirements.
Goal
1. To promote international harmonization
2. To make information available on ICH, ICH activities and
ICH guidelines to any country or company
3. To promote a mutual understanding of regional initiatives
4. To strengthen the capacity of drug regulatory authorities
and industry to utilize them.
Location
. The ICH Secretariat is based in Geneva
4
5. PHARMACEUTICAL QUALITY SYSTEMS
(ICH Q10)
• This document establishes a new ICH tripartite guideline describing a model for an
effective quality management system for the pharmaceutical industry
• ICH Q10 was adopted in the year 2008 to establish and implement an effective QA
system in order to comply with GMP.
• This guideline, “pharmaceutical quality systemic on ISO concept.
• ICH Q10 demonstrates industry and regulatory authorities’
• ICH Q10 is not intended to create any new expectations beyond current regulatory
requirements
• Current is Step 4, Version dated 4th June 2008
• Recommended for adoption to the regulatory bodies of the European Union,
Japan and USA
5
6. OBJECTIVES
(1) Achieve Product Realization:
To establish, implement & maintain a system that allows the delivery of a products
with the quality attributes appropriate to meet the needs of patient & other stake
holders.
(2) Establish & Maintain a State of Control:
To develop & use effective monitoring & control systems for process performance &
product quality, thereby providing assurance of continued suitability and capability
of processes. Quality Risk Management (QRM) can be useful in identifying the
monitoring and control systems
(3) Facilitate Continual Improvement:
To identify and implement appropriate product quality improvements, process
improvements, variability reduction, innovation & quality system enhancements,
thereby increasing the ability to fulfill quality needs consistently. QRM can be useful
for identifying & prioritizing areas for continual improvement 6
7. DESIGN AND CONTENT CONSIDERATIONS
• The pharmaceutical quality system should be well structured
• Facilitate common understanding and consistent application
• Product lifecycle stages, recognizing the differences among, and the different
goals of each stage
• Manufacturing of procurement of materials, provision of facilities, quality
control and assurance.
7
8. SCOPE
• This guideline applies to
• PHARMACEUTICAL DRUG SUBSTANCES AND DRUG PRODUCTS
Pharmaceutical Development
Drug substance development,
Novel excipient development,
Formulation development,
Delivery system development,
Manufacturing process development and scale-up,
Analytical method development.
• TECHNOLOGY TRANSFER
• New product transfers during Development through Manufacturing;
• Transfers within or between manufacturing and testing sites for marketed products.
8
9. Commercial Manufacturing:
• Acquisition and control of materials
• Provision of facilities, utilities & equipment;
• Production (including packaging and labeling);
• QC and QA
• Release, Storage
• Distribution (excluding wholesaler activities)
PRODUCT DISCONTINUATION:
• Retention of documentation
• Sample retention
• Continued product assessment and reporting
9
10. RELATIONSHIP OF ICH Q10 TO REGIONAL GMP REQUIREMENTS
• Q10 is not a harmonized GMP, Regional GMPs do not currently apply across the
product(s) life cycle but
• GMPs do provide guidance on manufacture and control of pharmaceutical products
• GMPs do provide guidance on most of the essential elements of a Quality Assurance
System
• GMPs address CAPA but not proactive continual improvement
• GMPs touch on management responsibilities
• GMPs do not address the system needed to bring a quality product to market
• However, GMPs are a critical element of an effective Pharmaceutical Quality System
10
11. RELATIONSHIP OF ICH Q10 TO REGULATORY APPROACHES
• Regulatory approaches for a specific product or manufacturing facility
• It should be commensurate with the level of product and process understanding
• to enhance science and risk based regulatory
• Regulatory processes will be determined by region.
• pharmaceutical quality system can normally be evaluated during a regulatory
inspection at the manufacturing site.
11
13. MANAAGEMENT REVIEW
• Management should have a formal process for reviewing the pharmaceutical
quality system on a periodic basis.
• i) Measurement of achievement of pharmaceutical quality system objectives
• ii) Assessment of Key Performance Indicators that can be used to monitor the
effectiveness of processes within the pharmaceutical quality system such as,
• Complaint, deviation, CAPA and change management processes;
• Self-assessment processes including audits
• External assessments such as regulatory inspections and findings and
customer audits.
13
14. APPLICABILITY AND KEY MASSAGE
• Pharmaceutical Quality System
• Scale-up and Technology Transfer
• Process Validation
• Change Management and Continual Improvement
• Quality Unit (QA/QC) and Batch Release
14
15. KEY MASSAGE
• It introduces the involvement and role of senior management
• It introduces a product life cycle perspective
• Quality Risk Management and Knowledge Management are enablers for the
PQS
• Implementation of PQS provides to enhance assurance of product quality
15
16. QRM-Quality Risk Management
• QRM is integral to an effective pharmaceutical quality system. It can provide
a proactive approach to identifying, scientifically evaluating & controlling
potential risks to quality. It facilitates continual improvement of process
performance & product quality throughout the product life cycle.
• QRM can be applied to different aspects of pharmaceutical quality
(e.g. Design & content consideration)
16
17. CHALLENGES
• Trust and Culture Change
• Industry-Regulatory Trust & Openness in vision
• Culture change in both for industry & regulatory
• Will the Q10 approach disadvantage small & medium manufacturing units?
• What is the scope of QMS (Site or Enterprise)?
• How many companies will require re-engineering of their QMS?
• How will we eventually adopte
17
18. CONCLUSIONS
• ICH Q10 requires an understanding of FDA for the 21st Century, ICH Q8 (Design), ICH
Q9 (Risk) as well as ISO 9000 (2005) to maximize benefit
• ICH Q10 is an ISO SYSTEMS approach to GMP
• NOT additional to GMP but integral to GMP
• Covers full life Cycle of a Product
• Objectives: Product Realization, Control & improvement
• Demands Management Team to lead Quality System and which protects public health in
respect of product lifecycle.
• As a management team we firmly believe that effective and robust Quality
• Risk Management underpinned by an effective quality system is key to the successful
implementation of the new concepts described in ICH Q8, Q9 & Q10.
18
19. REFERENCES
• International Conference on Harmonisation, ICH Q10: Pharmaceutical Quality
System, May 2007 & June 2008. http://www.ich.org/
• Guidance for Industry: Quality Systems Approach to Pharmaceutical GMP
Regulations, September 2006. http://www.fda.gov/
• International Conference on Harmonisation, ICH Q9: Quality Risk
Management, November 2005. http://www.ich.org/
• Kuchekar B.S., Khadatare A.M., Itkar S.C., Forensic Pharmacy, Nirali
Publication, page no.17.16-17.25.
19